
Ventas (VTR) Stock Forecast & Price Target
Ventas (VTR) Analyst Ratings
Bulls say
Ventas's diversified healthcare portfolio, comprising nearly 1,400 properties in senior housing, medical office spaces, hospitals, life sciences, and skilled nursing/post-acute care, positions the company well for sustained growth, particularly with an anticipated increase in SHOP concentration to over 50%. The estimated in-place net asset value (NAV) per share is projected to rise from $44.66 to $55.06 by year-end 2025, underscoring a robust growth outlook driven by strategic investments and a favorable operational environment. Additionally, with 29 operators collaborating, Ventas is poised to capitalize on its superior cost of capital to enhance accretive growth and potentially increase adjusted funds from operations (AFFO) estimates by over 10%.
Bears say
The financial outlook for Ventas is negatively impacted by an anticipated deterioration in the company’s cost of capital, limiting its ability to pursue new investment opportunities, which could lead to a decline in adjusted funds from operations (AFFO) estimates. Moreover, the outlook for senior housing operating properties (SHOP) appears muted, with expectations of modest occupancy growth coupled with overall expense increases that may offset revenue growth, thus compressing valuation multiples. Additionally, a net debt to EBITDA ratio of 6.0x, exceeding the target range, alongside potential reductions in funding from the National Institutes of Health (NIH), pose significant risks to the company’s financial stability and growth prospects.
This aggregate rating is based on analysts' research of Ventas and is not a guaranteed prediction by Public.com or investment advice.
Ventas (VTR) Analyst Forecast & Price Prediction
Start investing in Ventas (VTR)
Order type
Buy in
Order amount
Est. shares
0 shares